News
World Health Organization (WHO) member countries adopted a new treaty on May 20, 2025, to improve international coordination ...
Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.
An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K. regulators cleared Sarepta to restart an Elevidys study and Altos Labs ...
The Conversation asked Nicole Hassoun, a professor at Binghamton University and executive director of Global Health Impact, ...
Global health leaders called for the Pandemic Agreement adopted at the 78th World Health Assembly to deliver where past efforts failed—equitable access to life-saving technologies and services during ...
While gaps persist in workforce retention, infrastructure, and equitable access, the transformation of Nigeria’s health ...
Pfizer has struck a high-stakes deal with 3SBio to license SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside of China. Unlike current drugs that hit only PD-1, this antibody aims at two ...
Hinge Health Inc. and a group of investors raised $437 million in the digital physical therapy provider’s US initial public ...
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it the Supreme Court of Korea has ruled in its favor in ...
Ralph Hughes joins Faron to strengthen Commercial Strategy, Business Development and Market Assessment function TURKU, FI / ACCESS Newswire / May 21, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First ...
The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results